These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 15948275)

  • 21. Tenofovir helps beat hepatitis B.
    TreatmentUpdate; 2003 Jan; 15(1):4. PubMed ID: 12630369
    [No Abstract]   [Full Text] [Related]  

  • 22. Tenofovir works as pre-exposure prophylaxis against HIV, two studies confirm.
    Roehr B
    BMJ; 2011 Jul; 343():d4540. PubMed ID: 21765115
    [No Abstract]   [Full Text] [Related]  

  • 23. [One year with Atripla. Changeover to complete HIV therapy in a single tablet has proven successful].
    Warpakowski A
    MMW Fortschr Med; 2009 Apr; 151(18):54-5. PubMed ID: 19769077
    [No Abstract]   [Full Text] [Related]  

  • 24. The role of tenofovir in the prevention of HIV infections.
    De Clercq E
    AIDS; 2006 Oct; 20(15):1990-1. PubMed ID: 16988528
    [No Abstract]   [Full Text] [Related]  

  • 25. Five-year data out on Viread.
    AIDS Patient Care STDS; 2006 Dec; 20(12):887-8. PubMed ID: 17219618
    [No Abstract]   [Full Text] [Related]  

  • 26. Selection of L74V mutation in reverse transcriptase of HIV-1 subtype D by a tenofovir DF-lamivudine based regimen.
    Tamalet C; Tomei C; Henry M; Solas C; Villacian J; Colson P
    AIDS; 2007 Nov; 21(18):2551-2. PubMed ID: 18025898
    [No Abstract]   [Full Text] [Related]  

  • 27. [96-week treatment outcome confirms long term efficacy of tenofovir DF].
    Dtsch Med Wochenschr; 2003 May; 128(19):1074-5. PubMed ID: 12774796
    [No Abstract]   [Full Text] [Related]  

  • 28. Effects of the change from Stavudine to tenofovir in human immunodeficiency virus-infected children treated with highly active antiretroviral therapy: studies on mitochondrial toxicity and thymic function.
    Rosso R; Nasi M; Di Biagio A; Repetto E; Dentone C; Pinti M; Nemes E; Ferraresi R; Mussini C; Esposito R; Viscoli C; Cossarizza A
    Pediatr Infect Dis J; 2008 Jan; 27(1):17-21. PubMed ID: 18162932
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tenofovir and didanosine: a dangerous liaison.
    Waters L; Maitland D; Moyle GJ
    AIDS Read; 2005 Aug; 15(8):403-6, 413. PubMed ID: 16110555
    [No Abstract]   [Full Text] [Related]  

  • 30. [Medication change due to side effects or possible long-term complications. Side effect management with vision].
    Sankawa Y
    MMW Fortschr Med; 2009 Apr; 151(18):35. PubMed ID: 19769072
    [No Abstract]   [Full Text] [Related]  

  • 31. Marked elevation of the creatine phosphokinase level in a patient receiving tenofovir.
    Shere-Wolfe KD; Verley JR
    Clin Infect Dis; 2002 Nov; 35(9):1137. PubMed ID: 12384851
    [No Abstract]   [Full Text] [Related]  

  • 32. CD4+ T cell evolution and predictors of its trend before and after tenofovir/didanosine backbone in the presence of sustained undetectable HIV plasma viral load.
    Torti C; Lapadula G; Barreiro P; Soriano V; Mandalia S; De Silvestri A; Suter F; Maggiolo F; Antinori A; Antonucci F; Maserati R; El Hamad I; Pierotti P; Sighinolfi L; Migliorino G; Ladisa N; Carosi G;
    J Antimicrob Chemother; 2007 Jun; 59(6):1141-7. PubMed ID: 17434879
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination antiretroviral therapy with tenofovir, emtricitabine or lamivudine, and nevirapine.
    Redfield RR; Morrow JS
    Clin Infect Dis; 2008 Oct; 47(7):984-5. PubMed ID: 18778234
    [No Abstract]   [Full Text] [Related]  

  • 34. Comment on: suboptimal CD4 gains in HIV-infected patients receiving didanosine plus tenofovir.
    Anderson PL; Kakuda TN
    J Antimicrob Chemother; 2006 Jul; 58(1):220-1. PubMed ID: 16717052
    [No Abstract]   [Full Text] [Related]  

  • 35. Tenofovir for the treatment of hepatitis B virus.
    Jenh AM; Thio CL; Pham PA
    Pharmacotherapy; 2009 Oct; 29(10):1212-27. PubMed ID: 19792994
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Stakeholder consultation to address issues related to tenofovir prophylactic research.
    Halima Y; Collins C
    IAPAC Mon; 2005 Jun; 11(6):166-9. PubMed ID: 16276586
    [No Abstract]   [Full Text] [Related]  

  • 37. Hepatitis B reverse seroconversion in HIV-positive patients: case series and review of the literature.
    Rouphael NG; Talati NJ; Rimland D
    AIDS; 2007 Mar; 21(6):771-4. PubMed ID: 17413702
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tenofovir-associated kidney diseases and interactions between tenofovir and other antiretrovirals.
    Lanzafame M; Lattuada E; Rapagna F; Gottardi M; Vento S
    Clin Infect Dis; 2006 Jun; 42(11):1656-7; author reply 1658. PubMed ID: 16652329
    [No Abstract]   [Full Text] [Related]  

  • 39. Interruptions of tenofovir/emtricitabine-based antiretroviral therapy in patients with HIV/hepatitis B virus co-infection.
    Nüesch R; Ananworanich J; Srasuebkul P; Chetchotisakd P; Prasithsirikul W; Klinbuayam W; Mahanontharit A; Jupimai T; Ruxrungtham K; Hirschel B
    AIDS; 2008 Jan; 22(1):152-4. PubMed ID: 18090405
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reduced glomerular filtration rate but sustained virologic response in HIV/hepatitis B co-infected individuals on long-term tenofovir.
    Tan LK; Gilleece Y; Mandalia S; Murungi A; Grover D; Fisher M; Atkins M; Nelson M
    J Viral Hepat; 2009 Jul; 16(7):471-8. PubMed ID: 19457140
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.